NasdaqGS:CBAY

Stock Analysis Report

Executive Summary

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • CymaBay Therapeutics has significant price volatility in the past 3 months.

Share Price & News

How has CymaBay Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.5%

NasdaqGS:CBAY

-1.6%

US Pharmaceuticals

-1.9%

US Market


1 Year Return

-55.6%

NasdaqGS:CBAY

-8.5%

US Pharmaceuticals

-3.3%

US Market

CBAY underperformed the Pharmaceuticals industry which returned -8.4% over the past year.

CBAY underperformed the Market in United States of America which returned -3% over the past year.


Share holder returns

CBAYIndustryMarket
7 Day-3.5%-1.6%-1.9%
30 Day-13.3%-4.5%-6.2%
90 Day-55.0%-5.5%0.3%
1 Year-55.6%-55.6%-6.3%-8.5%-1.1%-3.3%
3 Year126.6%126.6%8.4%1.0%37.9%28.9%
5 Year1.3%1.3%20.1%7.5%50.8%34.1%

Price Volatility Vs. Market

How volatile is CymaBay Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CymaBay Therapeutics undervalued based on future cash flows and its price relative to the stock market?

1.61x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for CymaBay Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for CymaBay Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

CymaBay Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.

CymaBay Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for CymaBay Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

CymaBay Therapeutics is good value based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is CymaBay Therapeutics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

35.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

CymaBay Therapeutics's revenue is expected to grow significantly at over 20% yearly.

CymaBay Therapeutics's earnings are expected to grow significantly at over 20% yearly.

CymaBay Therapeutics's revenue growth is expected to exceed the United States of America market average.

CymaBay Therapeutics's earnings growth is expected to exceed the United States of America market average.

CymaBay Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if CymaBay Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has CymaBay Therapeutics performed over the past 5 years?

-64.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

CymaBay Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare CymaBay Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare CymaBay Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if CymaBay Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if CymaBay Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if CymaBay Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is CymaBay Therapeutics's financial position?


Financial Position Analysis

CymaBay Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

CymaBay Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

CymaBay Therapeutics has no debt.

CymaBay Therapeutics has no debt compared to 5 years ago when it was 52.9%.

CymaBay Therapeutics has no debt, it does not need to be covered by operating cash flow.

CymaBay Therapeutics has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

CymaBay Therapeutics has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is CymaBay Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate CymaBay Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate CymaBay Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as CymaBay Therapeutics has not reported any payouts.

Unable to verify if CymaBay Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as CymaBay Therapeutics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of CymaBay Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of CymaBay Therapeutics's salary, the management and board of directors tenure and is there insider trading?

2.4yrs

Average management tenure


CEO

Sujal Shah (46yo)

2.4yrs

Tenure

US$1,938,017

Compensation

Mr. Sujal A. Shah has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah served as an Interim Chief Executive Officer and Interim President of Cym ...


CEO Compensation Analysis

Sujal's remuneration is about average for companies of similar size in United States of America.

Sujal's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.4yrs

Average Tenure

57yo

Average Age

The tenure for the CymaBay Therapeutics management team is about average.


Board Age and Tenure

3.8yrs

Average Tenure

52yo

Average Age

The tenure for the CymaBay Therapeutics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$65,39921 Dec 18
Sujal Shah
EntityIndividual
Role
Chief Executive Officer
President
Shares10,000
Max PriceUS$6.54
SellUS$1,123,58819 Dec 18
Abingworth LLP
EntityCompany
Shares142,381
Max PriceUS$8.17
BuyUS$49,50016 Oct 18
Sujal Shah
EntityIndividual
Role
Chief Executive Officer
President
Shares5,000
Max PriceUS$9.90

Ownership Breakdown


Management Team

  • Klara Dickinson-Eason (51yo)

    Chief Regulatory & Compliance Officer

    • Tenure: 0.6yrs
  • Paul Quinlan (56yo)

    General Counsel & Corporate Secretary

    • Tenure: 1.7yrs
    • Compensation: US$2.96m
  • Patrick O'Mara (58yo)

    Senior Vice President of Business Development

    • Tenure: 2.6yrs
  • Charles McWherter (64yo)

    Senior VP & Chief Scientific Officer

    • Tenure: 6.6yrs
    • Compensation: US$1.79m
  • Rob Martin (57yo)

    Senior Vice President of Manufacturing & Nonclinical Development

    • Tenure: 4.3yrs
  • Pol Boudes (62yo)

    Chief Medical Officer

    • Tenure: 5.3yrs
    • Compensation: US$1.59m
  • Sujal Shah (46yo)

    President

    • Tenure: 2.4yrs
    • Compensation: US$1.94m
  • Ken Boehm

    Vice President of Human Resources

    • Tenure: 0.3yrs
  • Rob Wills (65yo)

    Chairman

    • Tenure: 3.8yrs
    • Compensation: US$183.53k
  • Dan Menold (49yo)

    Vice President of Finance

    • Tenure: 2.3yrs
    • Compensation: US$857.26k

Board Members

  • Carl Goldfischer (60yo)

    Independent Director

    • Tenure: 16.0yrs
    • Compensation: US$181.03k
  • Paul Truex (50yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$171.53k
  • Kurt von Emster (52yo)

    Independent Director

    • Tenure: 10.3yrs
    • Compensation: US$175.28k
  • Jerrold Olefsky

    Member of Clinical Advisory Board and Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Mayer Davidson

    Member of Clinical Advisory Board

    • Tenure: 0.0yrs
  • Morris Birnbaum

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Steve Shoelson

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Robert Gelfand

    Member of Clinical Advisory Board

    • Tenure: 0.0yrs
  • Sujal Shah (46yo)

    President

    • Tenure: 2.4yrs
    • Compensation: US$1.94m
  • Rob Wills (65yo)

    Chairman

    • Tenure: 3.8yrs
    • Compensation: US$183.53k

Company Information

CymaBay Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CymaBay Therapeutics, Inc.
  • Ticker: CBAY
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$379.917m
  • Shares outstanding: 68.70m
  • Website: https://www.cymabay.com

Number of Employees


Location

  • CymaBay Therapeutics, Inc.
  • 7575 Gateway Boulevard
  • Suite 110
  • Newark
  • California
  • 94560
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBAYNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2014
C0IDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2014
0I5PLSE (London Stock Exchange)YesCommon StockGBUSDJan 2014

Biography

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/26 00:26
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.